The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.

VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.

A Vanderbilt study found that reducing dietary carbohydrates improved both symptoms and objective measurements of gastroesophageal reflux disease (GERD) in a randomized controlled trial.

Rarely fatal, the mpox virus — spread by close, often skin-to-skin contact — causes a painful, blistering rash, fever, chills and other symptoms.

Vanderbilt research shows that critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation lived more often when randomized to receive baricitinib.

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients.